🔍

Kwality Pharmaceuticals Ltd (539997)

📊 BSE: 539997 🏢 Pharmaceuticals 📢 Latest filing: 12 Aug 2026 📝 Analysis written: 13 Nov 2025

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, Kwality Pharmaceuticals' revenue was ₹162 Cr (+46.3% year on year, +3.4% on the previous quarter), and net profit ₹25.6 Cr (+113.5% year on year); the operating margin was 25.3%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹162	+46.3%	+3.4%
Operating profit	₹41.0	+70.9%	+5.2%
Net profit	₹25.6	+113.5%	+2.5%
EPS (₹)	24.69	+114.7%	+1.3%
Operating margin	25.3%	—	—

Full quarterly financials → Results calendar →

📢 Recent Corporate Announcements

Kwality Pharmaceuticals Conducts Investor Interaction on Business Operations and Outlook

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 12 Aug 2026, 03:49 PM

Kwality Pharmaceuticals held a virtual investor interaction on August 10, 2026, to discuss its business operations and performance outlook. The session, organized by Go India Advisors, relied on publicly available information with no unpublished price sensitive information (UPSI) disclosed. This follows a strong FY26 where the company achieved its revenue target of Rs 503 Cr, representing significant growth over FY25's Rs 370 Cr. Investors should note the company's ongoing transition toward high-margin biologics and complex injectables.

Virtual interaction held on August 10, 2026, at 4:00 P.M. IST.
Management discussed business performance following a year where revenue reached Rs 503 Cr.
The company maintains a target growth rate of 35% driven by new product launches.
No unpublished price sensitive information (UPSI) was shared during the session.

💡 Investors should review the provided audio/video recording for management's specific commentary on the timeline for EU GMP audits and the commercialization of the Biologics pipeline.

Kwality Pharma targets Rs 700+ Cr revenue in FY27 and Rs 1500 Cr by FY30

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 12 Aug 2026, 03:34 PM

Kwality Pharmaceuticals has provided aggressive growth guidance, targeting over Rs 700 Cr revenue in FY27, a ~40% increase from FY26. Management expects EBITDA margins to improve to 26-27% (up from 23.5% TTM) as the product mix shifts toward Oncology, which is targeted to reach 25-30% of sales by Q4 FY27. A new hormone plant (Unit 6) is scheduled to commence in November 2026, and the company has set a long-term revenue milestone of Rs 1500 Cr by FY30. Clinical trials for its first biosimilar, Erythropoietin, are expected to begin in late 2026 with commercialization by late 2027.

FY27 revenue guidance set at Rs 700+ Cr, representing 39% growth over FY26 revenue of Rs 503 Cr
EBITDA margin guidance of 26-27% exceeds the current TTM operating margin of 23.5%
Unit 6 Hormone plant to commence operations by November 2026
Long-term FY30 revenue target of Rs 1500 Cr, implying a 3x scale-up from FY26 levels
Oncology segment targeted to contribute 25-30% of total revenue by Q4 FY27

💡 Watch for the successful commissioning of the Hormone plant in November 2026 and the initiation of Erythropoietin clinical trials in Q3 FY27 as key execution milestones.

Kwality Pharma guides for Rs 700 Cr+ FY27 revenue and Rs 1500 Cr by FY30

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 12 Aug 2026, 03:33 PM

Kwality Pharmaceuticals has issued aggressive growth guidance, targeting over Rs 700 Cr revenue in FY27, representing a ~40% increase over TTM revenue of Rs 502 Cr. Management expects EBITDA margins to expand to 26-27% (vs TTM OPM of 23.5%) driven by a shift toward high-margin oncology and hormone products. The company's sixth unit (Hormone plant) is scheduled to commence in November 2026, while clinical trials for its first biosimilar (Erythropoietin) are set for late 2026. Long-term targets aim for Rs 1500 Cr revenue by FY30, with a significant contribution expected from European and LATAM markets.

FY27 revenue guidance of Rs 700 Cr+ implies ~40% growth over TTM revenue of Rs 502 Cr
EBITDA margin guidance raised to 26-27% from current TTM levels of 23.5%
Unit 6 (Hormone plant) to commence operations by November 2026
Secured 60-70 new product registrations in the last three quarters, each contributing Rs 12-16 Cr annually
Long-term FY30 revenue target set at Rs 1500 Cr, nearly 3x current TTM revenue

💡 Monitor the timely commencement of the Hormone plant in November 2026 and the start of Erythropoietin clinical trials in December 2026 as key execution milestones. Investors should also track the oncology revenue mix, which management aims to scale to 25-30% by Q4 FY27.

Kwality Pharma raises FY27 revenue guidance to Rs 700+ Cr; Q1 PAT jumps 119% YoY

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 10 Aug 2026, 12:40 PM

Kwality Pharmaceuticals reported a robust Q1FY27 with revenue growing 45.7% YoY to Rs 162.4 Cr and PAT surging 119.3% YoY to Rs 25.7 Cr. Management has upgraded its FY27 revenue guidance to Rs 700+ Cr (up from Rs 650 Cr), implying a 39%+ growth over FY26. Profitability outlook is also raised with EBITDA margins targeted at 27-28%+, driven by a shift toward high-margin oncology, biologics, and complex injectables. The company is on track to complete its new hormone facility (Unit 6) by Q3CY26.

Q1FY27 Revenue increased 45.7% YoY to Rs 162.4 Cr, representing ~32% of TTM revenue in a single quarter
FY27 Revenue guidance raised to Rs 700+ Cr from previous Rs 650 Cr, targeting 39% YoY growth
PAT guidance for FY27 raised to Rs 109+ Cr, a significant jump from FY26 actual PAT of Rs 67 Cr
Cash conversion cycle improved drastically to 161 days in FY26 from 297 days in FY23
Unit 6 (Hormones) construction is underway with expected completion by Q3CY26

💡 Watch for the successful commercialization of the first biologic, Erythropoietin, in H1FY28 and the outcome of upcoming EU-GMP audits which are critical for regulated market entry.

119% YoY PAT Growth in Q1 FY27; Management Raises FY27 Revenue Guidance to ₹700+ Cr

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 10 Aug 2026, 12:27 PM

Kwality Pharmaceuticals reported a strong start to FY27, with consolidated revenue growing 46% YoY to ₹162.35 Cr and PAT surging 119% YoY to ₹25.62 Cr. EBITDA margins expanded to 25.3% from 21.9% YoY, reflecting a shift toward higher-margin complex injectables and biologics. Management has significantly raised its FY27 guidance, now targeting revenue of ₹700+ Cr (up from ₹503 Cr in FY26) and PAT of ₹109+ Cr. The company also completed 13 Bioequivalence studies and secured 15+ new product registrations globally during the quarter.

Consolidated revenue increased 46% YoY to ₹162.35 Cr for the quarter ended June 30, 2026.
Net Profit (PAT) surged 119% YoY to ₹25.62 Cr, with PAT margins improving from 11% to 16%.
Management raised FY27 revenue guidance to ₹700+ Cr, representing a ~39% growth over FY26.
Completed 13 Bioequivalence (BE) studies as part of a 40-molecule program across General, Beta Lactam, and Oncology units.
Hormone manufacturing facility construction is on track for completion by November 2026.

💡 Monitor the timely completion of the Hormone facility in November 2026 and the clinical trial progress of biologics like Erythropoietin, which are key to achieving the upgraded FY27 guidance.

119% PAT Growth in Q1 FY27; Management Raises FY27 Revenue Guidance to ₹700+ Cr

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 10 Aug 2026, 12:09 PM

Kwality Pharmaceuticals reported a strong start to FY27 with consolidated revenue growing 46% YoY to ₹162.35 cr and PAT surging 119% YoY to ₹25.62 cr. The company achieved significant margin expansion, with PAT margins rising from 11% to 16% YoY, driven by a shift toward high-barrier products. Management has notably raised its FY27 revenue guidance to ₹700+ cr, a ~39% increase over FY26 revenue of ₹503 cr. Operational progress remains robust with 13 Bioequivalence studies completed and a new hormone facility scheduled for completion by November 2026.

Consolidated revenue increased 46% YoY to ₹162.35 cr in Q1 FY27 compared to ₹111.48 cr in Q1 FY26.
Net profit (PAT) surged 119% YoY to ₹25.62 cr, with EPS rising to ₹24.69 from ₹11.49.
Management raised FY27 revenue guidance to ₹700+ cr, significantly higher than the previous ₹500 cr target.
Completed 13 Bioequivalence (BE) studies during the quarter as part of a 40-molecule program.
Hormone manufacturing facility construction is on track for completion by November 2026.

💡 Investors should monitor the timely completion of the Hormone facility in November 2026 and the progress of biologics candidates like Erythropoietin through clinical trials, which are key to the upgraded guidance.

Kwality Pharma targets ₹700 Cr+ FY27 revenue; FY26 PAT grows 69% to ₹67.3 Cr

🟢 POSITIVE ⭐ 7/10

BOARD_MEETING 📅 09 Aug 2026, 11:34 PM

Kwality Pharmaceuticals successfully met its three-year target of doubling revenue, reporting ₹503 Cr for FY26, a 36% YoY increase. Profitability outpaced revenue growth, with PAT surging 69% to ₹67.3 Cr and EBITDA margins expanding 200 bps to 24%. Management has upgraded its FY27 revenue guidance to over ₹700 Cr (from ₹650 Cr) and set a long-term goal of ₹1,000 Cr by FY29. The company is pivoting toward high-margin biologics and complex injectables, with its first biologic launch planned for CY2027.

FY26 consolidated revenue reached ₹503 Cr, achieving the three-year doubling target from FY23.
Profit After Tax (PAT) grew 69% YoY to ₹67.3 Cr, with PAT margins improving from 10.8% to 13.4%.
FY27 revenue guidance upgraded to >₹700 Cr, representing a ~40% growth target over FY26.
Cash conversion cycle improved to 170 days in FY26 from 208 days in FY25.
First biologic (Erythropoietin) achieved successful pre-clinical outcomes, targeting a CY2027 launch.

💡 Monitor the execution of the upgraded FY27 revenue guidance and the outcome of EU GMP audits for the General and Beta Lactam units, which are critical for high-regulated market entry.

Kwality Pharma FY26 Revenue Hits ₹503 Cr; FY27 Guidance Raised to >₹700 Cr

🟢 POSITIVE ⭐ 7/10

ROUTINE 📅 09 Aug 2026, 11:28 PM

Kwality Pharmaceuticals successfully met its three-year target of doubling revenue, reaching ₹503 crore in FY26 (up 36% YoY). Profitability outpaced revenue growth, with PAT rising 69% to ₹67.3 crore and EBITDA margins expanding 200 bps to 24%. Management has upgraded its FY27 revenue guidance to over ₹700 crore (previously ₹650 crore) and set a long-term target of ₹1,000 crore by FY29. The company is pivoting toward complex injectables and biologics, with its first biologic launch (Kwalipoietin) slated for CY2027.

FY26 consolidated revenue reached ₹503 crore, achieving the 3-year doubling target from ₹250 crore in FY23.
FY27 revenue guidance upgraded to >₹700 crore, representing a ~39% growth target over FY26.
PAT grew 69% YoY to ₹67.3 crore, with PAT margins improving from 10.8% to 13.4%.
Cash conversion cycle improved to 170 days from 208 days, despite elevated debtor days of 208 due to Middle East conflicts.
Initiated bioequivalence programs for 40+ oral solid molecules and development of 3 new monoclonal antibodies (mAbs).

💡 Investors should monitor the successful completion of EU GMP audits for the General and Beta Lactam units, which is a prerequisite for entering high-regulated markets. Additionally, track the clinical progress of the lead biologic 'Kwalipoietin' ahead of its planned CY2027 launch.

43rd Annual General Meeting Scheduled for August 31, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 08 Aug 2026, 08:32 PM

Kwality Pharmaceuticals has scheduled its 43rd Annual General Meeting (AGM) for August 31, 2026, at 12:00 noon via video conferencing. This follows a strong financial performance in FY26, where the company achieved a revenue of Rs 503 Cr and a PAT of Rs 67 Cr. The meeting is a standard regulatory requirement for shareholders to adopt financial statements and approve corporate resolutions. Investors should monitor the upcoming detailed AGM notice for any dividend declarations or strategic updates regarding their biologics expansion.

43rd Annual General Meeting to be held on August 31, 2026
Meeting scheduled for 12:00 noon via Video Conference (VC) / Other Audio Visual Means (OAVM)
Company reported TTM revenue of Rs 502 Cr and TTM PAT of Rs 67 Cr
Promoter holding remains stable at 54.87% as of March 2026

💡 Review the upcoming Annual Report for management commentary on the progress of EU GMP audits and the launch timeline for new Biologics like Teriparatide.

Kwality Pharmaceuticals to hold 43rd Annual General Meeting on August 31, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 08 Aug 2026, 08:29 PM

Kwality Pharmaceuticals has scheduled its 43rd Annual General Meeting (AGM) for August 31, 2026, to be conducted virtually. This follows a strong FY26 performance where the company achieved its revenue target of ₹503 crore, a significant increase from ₹370 crore in FY25. The meeting will likely cover the company's progress on its Biologics launch (Teriparatide, Enoxaparin) and the status of EU GMP audits for its manufacturing units. With a current market cap of ₹2,737 crore and a TTM PAT of ₹67 crore, the company is trading at a P/E of 40.9.

43rd Annual General Meeting scheduled for August 31, 2026, at 12:00 noon
Company achieved FY26 revenue of ₹503 crore, representing ~36% year-on-year growth
TTM PAT stands at ₹67 crore with an Operating Profit Margin of 23.5%
Promoter holding remains stable at 54.87% as of March 2026

💡 Investors should review the upcoming Annual Report for specific updates on the EU GMP audit timeline and the commercialization status of new complex injectables and biologics.

Kwality Pharmaceuticals to Hold 43rd AGM on Aug 31; Re-appoints WTD for 5-Year Term

🟡 NEUTRAL ⭐ 3/10

BOARD_MEETING 📅 08 Aug 2026, 08:25 PM

Kwality Pharmaceuticals has scheduled its 43rd Annual General Meeting (AGM) for August 31, 2026, via video conferencing. The Board approved the re-appointment of Mr. Aditya Arora as Whole Time Director for a five-year term effective September 30, 2026, ensuring leadership continuity. Additionally, the company fixed August 24, 2026, as the cut-off date for e-voting eligibility. These administrative steps follow a strong FY26 where the company achieved Rs 503 Cr in revenue, meeting its growth targets.

43rd Annual General Meeting scheduled for August 31, 2026, at 12:00 noon
Cut-off date for e-voting eligibility set for August 24, 2026
Re-appointment of Mr. Aditya Arora as Whole Time Director for a 5-year term until September 2031
Book closure period fixed from August 25, 2026, to August 31, 2026
Appointment of M/s Verma Khushwinder & Co. as Cost Auditors for the financial year 2026-27

💡 Investors should review the upcoming AGM notice for detailed management commentary on the progress of EU GMP audits and the launch of new Biologics, which are key to the company's high-margin growth strategy.

Kwality Pharmaceuticals Schedules Q1 FY27 Earnings Call for August 10, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 04 Aug 2026, 06:18 PM

Kwality Pharmaceuticals has scheduled its Q1 FY2026-27 earnings conference call for August 10, 2026, at 4:00 PM IST. This follows a strong FY26 performance where the company achieved its revenue target of Rs 503 Cr, up from Rs 370 Cr in FY25. Investors will be looking for updates on the company's strategic shift toward biologics and the status of EU GMP audits for its manufacturing units. The company currently maintains a healthy Operating Profit Margin of 24% and a ROCE of 24%.

Earnings conference call scheduled for August 10, 2026, at 4:00 PM IST
Company achieved FY26 revenue of Rs 503 Cr, representing a 36% year-on-year growth
Net profit for FY26 reached Rs 67 Cr compared to Rs 40 Cr in FY25
Management participation includes Managing Director Ramesh Kumar and CFO Aditya Arora

💡 Monitor the earnings call for management commentary on the timeline for EU GMP approvals and the commercial launch of complex injectables like Teriparatide and Enoxaparin.

Kwality Pharmaceuticals Schedules Q1 FY27 Earnings Call for August 10, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 04 Aug 2026, 06:11 PM

Kwality Pharmaceuticals has scheduled its Q1 FY27 earnings conference call for August 10, 2026, at 4:00 PM IST. This follows a strong FY26 performance where the company achieved its revenue target of ₹503 Cr and a PAT of ₹67 Cr. Investors will likely focus on the progress of the EU GMP audits for the General and Beta Lactam units, which are critical for entering high-regulated markets. The company is currently transitioning toward high-margin biologics and complex injectables, supported by a TTM OPM of 23.5%.

Earnings conference call scheduled for Monday, August 10, 2026, at 4:00 PM IST
Company achieved FY26 revenue of ₹503 Cr, representing significant growth over FY25's ₹370 Cr
TTM PAT stands at ₹67 Cr with a current P/E ratio of 39.3
Management participants include Managing Director Ramesh Kumar and CFO Aditya Arora
Company is targeting 50+ product filings in high-regulated markets like the EU and South Africa for FY26

💡 Monitor the earnings call for management commentary on the timeline for EU GMP audit completions and the commercial launch status of biologics like Teriparatide and Enoxaparin.

Kwality Pharmaceuticals schedules Q1 FY27 earnings call for August 10, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 04 Aug 2026, 06:09 PM

Kwality Pharmaceuticals has scheduled its Q1 FY27 earnings conference call for August 10, 2026, at 4:00 PM IST. This follows a strong FY26 performance where the company achieved a revenue of Rs 503 crore, representing approximately 36% growth over FY25. Investors will be looking for updates on the company's strategic shift toward biologics and the status of EU GMP audits for its manufacturing units. The company currently maintains a healthy operating margin of 23.5% and a TTM PAT of Rs 67 crore.

Earnings conference call scheduled for August 10, 2026, at 4:00 PM IST
Company reported FY26 revenue of Rs 503 crore, meeting its previously stated growth targets
TTM PAT stands at Rs 67 crore with an EPS of Rs 64.92
Management participants include Managing Director Ramesh Kumar and CFO Aditya Arora
Call hosted by Go India Advisors; pre-registration is mandatory for login details

💡 Investors should listen for management commentary regarding the timeline for EU GMP audits and the commercial launch of biologics like Teriparatide and Enoxaparin.

Board Meeting on August 10, 2026, to Approve Q1 FY27 Financial Results

🟡 NEUTRAL ⭐ 3/10

BOARD_MEETING 📅 03 Aug 2026, 03:50 PM

Kwality Pharmaceuticals has scheduled a board meeting for August 10, 2026, to approve standalone and consolidated financial results for the quarter ended June 30, 2026. This follows a strong FY26 performance where the company achieved its revenue target of Rs 500 Cr, finishing at Rs 503 Cr with a 24% operating margin. The trading window for designated persons remains closed until 48 hours after the results are declared. Investors will be looking for the first performance indicators of FY27 and updates on the company's biologics expansion strategy.

Board meeting scheduled for August 10, 2026, to consider Q1 FY27 results.
Financial results for the quarter ended June 30, 2026, will be reviewed.
Trading window for designated persons has been closed since June 29, 2026.
Company achieved Rs 503 Cr revenue in FY26, representing ~36% growth over FY25.

💡 Monitor the Q1 FY27 results on August 10, 2026, specifically for updates on the EU GMP audit status and the launch of Biologics like Teriparatide.

View All 539997 Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated revenue from operations grew 20.52% YoY, reaching INR 370.20 Cr in FY25 compared to INR 307.17 Cr in FY24. Q1 FY26 revenue was reported at INR 111.9 Cr, indicating a strong start to the new fiscal year.

Geographic Revenue Split

The company exports to over 40 countries. While specific regional percentages are not disclosed, the company is actively expanding into high-regulated markets including the EU and South Africa, with approvals from authorities like ANVISA (Brazil), NAFDAC (Nigeria), and SFDA (Saudi Arabia).

Profitability Margins

Net Profit Margin (NPM) improved significantly to 10.8% in FY25 from 7.8% in FY24. Profit After Tax (PAT) rose 66.7% YoY to INR 39.88 Cr in FY25 from INR 23.92 Cr in FY24. Q1 FY26 NPM stood at 10.6%.

EBITDA Margin

EBITDA margin remained stable at 21.7% in FY25 (INR 80 Cr) compared to 21.7% in FY24 (INR 66 Cr). The company is projecting a margin expansion to 22-25% for FY26 through strategic efficiency initiatives.

Capital Expenditure

Property, Plant, and Equipment (PPE) increased to INR 143.98 Cr in FY25 from INR 139.05 Cr in FY24, representing a net addition of INR 4.93 Cr. Intangible assets of INR 1.71 Cr were added in FY25.

Credit Rating & Borrowing

The company is currently rated 'CRISIL B/Stable' and '[ICRA]B+(Stable)' under the 'Issuer Not Cooperating' category due to failure to provide requisite information. Interest coverage ratio improved to 8.14x in FY25 from 6.42x in FY24.

⚙️ Operational Drivers

Raw Materials

Primary costs include raw materials and packing materials, which totaled INR 165.41 Cr in FY25, representing 44.7% of total revenue. Stock-in-trade purchases increased significantly to INR 15.90 Cr from INR 0.85 Cr YoY.

Capacity Expansion

Current annual capacities include 1,800 million Tablets, 200 million Vials, 200 million Ampoules, 180 million Capsules, and 100 million Dry Powder Injections. Planned expansion includes the EU GMP audit of General and Beta Lactam units in FY26 to facilitate regulated market entry.

Raw Material Costs

Raw material costs as a percentage of revenue stood at 44.7% in FY25. Total expenses grew 20.3% YoY to INR 290 Cr, tracking closely with revenue growth.

Manufacturing Efficiency

The company operates five state-of-the-art facilities. Efficiency is driven by dedicated leadership teams for each unit (Generic, Beta Lactam, Oncology, Biologics) and a workforce of 700+ employees.

📈 Strategic Growth

Expected Growth Rate

35%

Growth Strategy

The company aims to reach INR 500 Cr revenue in FY26 by launching its first Biologics (Teriparatide, Enoxaparin) in India, achieving 50+ product approvals in global markets, and completing EU GMP audits for its General and Beta Lactam units. It is also positioning itself as a global supplier of peptide-based products.

Products & Services

The product portfolio includes Sterile Powder for Injection, Small Volume Parentals (Liquid and Lyophilized), Pre-filled Syringes (PFS), Tablets, Capsules, Liquid Orals, Ophthalmic Preparations, and Suppositories.

Brand Portfolio

Kwality Pharmaceuticals (KPL).

New Products/Services

New launches include Biologics (Teriparatide, Enoxaparin, Liraglutide) and complex injectables such as Liposomal Pegylated and Peptide-based technology products.

Market Expansion

Targeting high-regulated markets (EU, South Africa) with 50+ product filings planned for FY26.

Strategic Alliances

The company has partnered with domestic firms to launch Biologics in India while targeting global development independently.

🌍 External Factors

Industry Trends

The industry is shifting toward complex injectables and biologics. KPL is positioning itself for this transition by establishing a dedicated Biological Unit and initiating preclinical programs for its first biologics.

Competitive Landscape

Competes with global and domestic pharmaceutical manufacturers in the generic and complex injectable space.

Competitive Moat

KPL's moat is built on a 40-year legacy, 600+ regulatory successes, and specialized manufacturing capabilities in complex injectables (Lyophilized, PFS, Oncology), which have higher entry barriers than standard oral solids.

Macro Economic Sensitivity

The business is sensitive to global healthcare spending and regulatory changes in export markets like Brazil (ANVISA) and the UAE.

Consumer Behavior

Increased global demand for affordable complex injectables and biologics is driving the company's R&D focus.

Geopolitical Risks

Operations in Africa (Mozambique subsidiary) and filings in diverse global markets expose the company to regional political and economic instability.

⚖️ Regulatory & Governance

Industry Regulations

Operations are governed by stringent manufacturing standards including PIC/s GMP, SFDA, ANVISA, and upcoming EU GMP audits. Compliance with these is critical for maintaining export licenses.

Taxation Policy Impact

Tax expense for FY25 was INR 14 Cr, representing an effective tax rate of approximately 26% on Profit Before Tax of INR 54 Cr.

Legal Contingencies

The company's foreign subsidiary, Kwality Pharmaceuticals Africa Limitada, is unaudited and reported a net loss of INR 8.71 Lacs. No major pending litigation values were disclosed.

⚠️ Risk Analysis

Key Uncertainties

The 'Issuer Not Cooperating' status from CRISIL and ICRA is a major uncertainty that could impact financial flexibility. The success of the Biologics launch (Q3 FY26) is critical for meeting the INR 500 Cr revenue target.

Geographic Concentration Risk

While exporting to 40+ countries, the company is heavily reliant on the successful audit of its Indian facilities by international regulators to access the most lucrative markets.